Skip to main content

Clinical Therapeutics new Epilepsi Disease Analysis Research On Stedesa Pills, Anti Epileptics

Epilepsy Market 2019 Industry Size, Key Highlights, Growth Analysis, Clinical Therapeutics, Competitive Share, Regional Scope and Forecast To 2023

The anti-epilepsy drugs market is likely to expand at a steady pace across the globe. Market Research Future stated in its recently published reports that the worldwide anti-epilepsy drugs market is growing and can be estimated to gain momentum during 2017 to 2022. The market has been anticipated to reflect a consistent upsurge by the conclusion of 2022, surpassing its earlier growth records in terms of worth with a remarkable CAGR over the forecast period.

Global Epilepsy Market Key Players

The global anti-epilepsy drugs market has been dominated by key players such as Johnson & Johnson, Pfizer, Inc., Abbott, UCB Pharma Ltd., GlaxoSmithKline plc, Sanofi, Novartis AG, Cephalon Inc., and Shire Pharmaceuticals Limited. These are some of the noteworthy players at the forefront of rivalry in the global anti-epilepsy drugs market which have been profiled in MRFR Analysis

Browse complete The current research on epilepsy and epileptic meds on anti-epileptics

By condition, the ‘others’ segment accounted for 70.5% market share in 2017. It is touted to reach a worth close to USD 6,571.40 million by 2023. On the other hand, the drug resistant epilepsy segment is projected to reach a valuation of USD 2,937.80 million by the end of the forecast period. Emergence of rational polytherapy for treating the disorder with negligible side-effects is likely to accrue significant revenue for the epilepsy market.
By diagnosis & treatment, the treatment segment held 66.2% share of the epilepsy market in 2017. The segment can exhibit 7.91% CAGR during the forecast period due to availability of affordable drugs for treating partial epileptic seizures. In addition, approval of effective drugs by regulatory agencies can facilitate growth in the segment. It is expected to be worth USD 6,198.63 million by 2023. On the other hand, the diagnosis segment is predicted to enjoy 8.76% CAGR over the assessment period. Utilization of various imaging tests and blood tests for early discernment of the disorder is expected to drive the segment growth exponentially. For instance, CT scans are used for revealing abnormalities in the brain which can catch the probability of epilepsy at an early stage.

Labels:

Comments

Post a Comment

Popular posts from this blog

Hemifacial Spasm Market Application Scope, Types, Technology Benefits and Global Business

  Hemifacial Spasm Market  Research Information: By Diagnosis (Mri, Ct Or Cat Scan, Angiography (Arteriography)), Treatment (Medical Treatment, Surgical Treatment, Combinational Therapy, Tens, Physical Therapy, Others), End User – Global Forecast Till 2023 Market Highlights: Hemifacial spasm is a condition that causes frequent muscle spasms, on one side of the face. The condition can affect both men and women, but it is most prevalent in middle-aged or older women. Its incidence rate is also found to be higher among the Asian population. A number of factors such as increasing technological advancements, rising public awareness, increased incidence of craniofacial tremor, and facial chorea, unmet medical needs, increasing government assistance, improving regulatory framework, increasing adoption rate, and improvement in funding and reimbursement policies are propelling the growth of the global hemifacial spasm market. However, difficult diagnosis, cost of treatment, side-effect...
Post a Comment
Read more

U.S. Uterine Fibroid Market Latest Devices, Key Players Statistics Data, Regional Business Outlook 2022

U.S. Uterine Fibroid Market by Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), by Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2022 The  US Uterine Fibroid Market  report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report Major Key Players To gain a substantially large competitive advantage, these players incorporate strategic initiatives such as mergers & acquisitions, collaboration, expansion, and product launch. These are the Top Market...
Post a Comment
Read more

Global Merkel Cell Carcinoma Market Clincial Assessment and Professional Industry Outlook 2023

  Global Merkel Cell Carcinoma Market  Research Report: By Diagnosis (Physical Examination, Sentinel Node Biopsy, Imaging Test), Treatment (Surgery, Radiation Therapy, Chemotherapy), End User (Hospitals & Clinics, Diagnostic Centers) – Forecast till 2023 Market Highlights Increasing prevalence of Merkel cell carcinoma and growing geriatric population are estimated to be the major drivers for the market growth during the forecast period. Moreover, increasing R&D expenses by the key market players, rising mortality rate by MCC, and growing healthcare expenditure is further boosting the market growth. However, the high cost of therapeutics and related side effects along with the lack of awareness and low per capita healthcare expenditures in the developing economies restrains the market growth.  Intended Audience Pharmaceutical Companies Biotechnological Institutes Government and Private Laboratories Research and Development (R&D) Companies Medical Research Labor...
Post a Comment
Read more